Clinical trials
Hepatitis C trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
58 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 7 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 9 |
| 2012 | 6 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2023 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 35 |
| Unknown status | 16 |
| Terminated | 4 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 19 |
| Bristol-Myers Squibb | 10 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | 7 |
| Debiopharm International SA | 4 |
| GlaxoSmithKline | 3 |
| Boehringer Ingelheim | 2 |
| Gilead Sciences | 2 |
| AbbVie | 1 |
| Chang Gung Memorial Hospital | 1 |
| China Medical University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hepatitis C | 58 |
| Hepatitis C, Chronic | 12 |
| Hepatitis B | 8 |
| Acquired Immunodeficiency Syndrome | 3 |
| Fibrosis | 3 |
| Liver Diseases | 3 |
| Carcinoma, Hepatocellular | 2 |
| HIV Infections | 2 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Reinfection | 2 |
Trials
Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.